Treatment of antipsychotic-induced hyperprolactinemia: An update on the role of the dopaminergic receptors D2 partial agonist aripiprazole

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 8, Issue 1, 2014, Pages 30-37

  De Berardis, Domenico ^a,b   Fornaro, Michele ^c   Serroni, Nicola ^a   Marini, Stefano ^a   Piersanti, Monica ^a   Cavuto, Marilde ^d   Valchera, Alessandro ^e   Mazza, Monica ^f   Girinelli, Gabriella ^f   Iasevoli, Felice ^g   Perna, Giampaolo ^h,i,j   Martinotti, Giovanni ^b   Di Giannantonio, Massimo ^b  

^a G Mazzini Hospital   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d IASM   (Italy)

^e Hermanas Hospitalarias   (Italy)

^f UNIVERSITY OF L'AQUILA   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h Laboratory of Molecular Psychiatry and Psychopharmacotherapeutics Section of Psychiatry Department of Neuroscience University School of Medicine Federico II ^*  (Italy)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j MAASTRICHT UNIVERSITY   (Netherlands)

more..

Author keywords

Add on; Antipsychotics; Aripiprazole; Dopamine; Hyperprolactinaemia; Partial agonism; Prolactin; Switch; Update

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE DERIVATIVE; BLONANSERIN; CARBAMAZEPINE; CLOZAPINE; DECANOIC ACID; HALOPERIDOL; LEVOMEPROMAZINE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL DECANOATE; DOPAMINE 2 RECEPTOR; DRD2 PROTEIN, HUMAN; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; HUMAN; HYPERPROLACTINEMIA; MENTAL PATIENT; META ANALYSIS (TOPIC); PATENT; PATIENT MONITOR; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RELAPSE; TREATMENT RESPONSE; AGONISTS; CHEMICALLY INDUCED; DRUG COMBINATION; META ANALYSIS; PARTIAL AGONISM;

ANTIPSYCHOTIC AGENTS; DRUG PARTIAL AGONISM; DRUG THERAPY, COMBINATION; HUMANS; HYPERPROLACTINEMIA; PATENTS AS TOPIC; PIPERAZINES; QUINOLONES; RECEPTORS, DOPAMINE D2;

EID: 84895465195     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872214807666131229125700     Document Type: Article

References (88)

1. van Os J, Kapur S. Schizophrenia. Lancet 2009; 374: 635-45.
2. Ebisch SJ, Salone A, Ferri F, De Berardis D, Romani GL, Ferro FM, et al. Out of touch with reality? Social perception in firstepisode schizophrenia. Soc Cogn Affect Neurosci 2013; 8: 394-403.
3. Stahl SM, Morrissette DA, Citrome L, Saklad SR, Cummings MA, Meyer JM, et al. Meta-guidelines for the management of patients with schizophrenia. CNS Spectr 2013; 18: 150-62.
4. de Bartolomeis A, Buonaguro EF, Iasevoli F. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: From receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology 2013; 225:1-19.
5. Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics-a review. Hum Psychopharmacol Clin Exp 2010; 25: 281-97.
6. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: Differential risk and clinical implications. CNS Drugs 2007; 21: 911-36.
7. Uçok A, Gaebel W. Side effects of atypical antipsychotics: A brief overview. World Psychiatry 2008; 7: 58-62.
8. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2011; 1: CD006626.
9. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96.
10. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007; 64: 633.
11. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 2009; 373: 31-41.
12. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, et al. Efficacy, safety and early response of paliperidone extendedrelease tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007; 93: 117-30.
13. Bersani G, Gherardelli S, Clemente R, Di Giannantonio M, Grilli A, Conti CM, et al. Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics. J Clin Psychopharmacol 2005; 25: 372-5.
14. Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: A clinical review. Psychosomatics 2013; [Epub ahead of print].
15. Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol 2008; 22(2 Suppl): 90-7.
16. Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry 2011; 45: 830-7.
17. Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinaemia and antipsychotic treatment: A review and lessons for treatment of early psychosis. J Psychopharmacol 2012; 26: 42-51.
18. Kishimoto T, De Hert M, Carlson HE, Manu P, Correll CU. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry 2012; 25: 415-29.
19. Krysiak R, Ke{ogonek}dzia A, Okopień B. Unfavorable effects of hyperprolactinemia in autoimmune endocrine disorders. Neuro Endocrinol Lett 2012; 33: 298-300.
20. Coronas R, Cobo J, Giménez-Palop O, Ortega E, Márquez M. Safety of cabergoline in the management of pituitary prolactininduced symptoms with patients treated with atypical neuroleptics. Curr Drug Saf 2012; 7: 92-8.
21. De Berardis D, Serroni N, Campanella D, Marasco V, Moschetta FS, Di Giannantonio M. A case of Cotard's Syndrome successfully treated with aripiprazole monotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1347-8.
22. De Fazio P, Girardi P, Maina G, Mauri MC, Mauri M, Monteleone P, et al. Aripiprazole in acute mania and long-term treatment of bipolar disorder: A critical review by an Italian working group. Clin Drug Investig 2010; 30: 827-41.
23. Shah SK. A comparative study of sexual dysfunction in schizophrenia patients taking aripiprazole versus risperidone. Kathmandu Univ Med J 2013; 11: 121-5.
24. De Berardis D, Serroni N, Moschetta FS, Martinotti G, Di Giannantonio M. Reversal of aripiprazole-induced tardive akathisia by addition of pregabalin. J Neuropsychiatry Clin Neurosci 2013; 25: E9-10
25. De Berardis D, Acciavatti T, Campanella D, Serroni N, Olivieri L, Ranalli C, et al. Novel approaches in the treatment of antipsychotic-induced hyperprolactinemia: The role of partial agonists of d2 dopaminergic receptors. Recent Pat Endocr Metab Immune Drug Discov 2010; 4: 230-40.
26. Mir A, Shivakumar K, Williamson RJ, McAllister V, O'Keane V, Aitchison KJ. Change in sexual dysfunction with aripiprazole: A switching or add-on study. J Psychopharmacol 2008; 22: 244-53.
27. Lorenz RA, Weinstein B. Resolution of haloperidol-induced hyperprolactinemia with aripiprazole. J Clin Psychopharmacol 2007; 27: 524-25.
28. Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 2005; 162: 1542-3.
29. Chen JX, Su YA, Wang SL, Bian QT, Liu YH, Wang N, et al. Aripiprazole treatment of risperidone-induced hyperprolactinemia. J Clin Psychiatry 2009; 70: 1058-9.
30. Lin SK, Chen CK. Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report. J Clin Psychiatry 2006; 67: 1307.
31. Rainka MM, Capote HA, Ross CA, Gengo FM. Attenuation of risperidone-induced hyperprolactinemia with the addition of aripiprazole. J Clin Pharm Ther 2009; 34: 595-8.
32. Wolf J, Fiedler U. Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J Clin Pharm Ther 2007; 32: 197-8.
33. Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: Meta-analysis of randomized controlled trials. PLoS One 2013; 8: e70179.
34. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: A placebocontrolled trial. Am J Psychiatry 2007; 164: 1404-10.
35. Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-Week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009; 70: 1348-57.
36. Byerly MJ, Marcus RN, Tran QV, Eudicone JM, Whitehead R, Baker RA. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: Analysis of a randomized, open-label study. Schizophr Res 2009; 107: 218-22.
37. Hill SA, Khan AA, Wetherill M. Aripiprazole use combined with depot antipsychotic medication: Two cases demonstrating its ability to reduce prolactin levels in an adolescent forensic hospital. Ther Adv Psychopharmacol 2011; 1: 77-9.
38. Anandarajan T, Tibrewal P, Dhillon R, Bastiampillai T. Hyperprolactinaemia on depot risperidone treated with aripiprazole. Aust N Z J Psychiatry 2012; 46: 792-3.
39. Basterreche N, Zumárraga M, Arrue A, Olivas O, Dávila W. Aripiprazole reverses paliperidoneinduced hyperprolactinemia. Actas Esp Psiquiatr 2012; 40: 290-2.
40. Ishitobi M, Kosaka H, Shukunami K, Murata T, Wada Y. Adjunctive treatment with low-dosage aripiprazole for blonanserininduced hyperprolactinemia in a female patient with schizophrenia Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1361-2.
41. Chen CK, Huang YS, Ree SC, Hsiao CC. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1495-9.
42. Yasui-Furukori N, Furukori H, Sugawara N, Fujii A, Kaneko S. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol 2010; 30: 596-9.
43. van Kooten M, Arends J, Cohen D. Preliminary report: A naturalistic study of the effect of aripiprazole addition on risperidonerelated hyperprolactinemia in patients treated with risperidone long-acting injection. J Clin Psychopharmacol 2011; 31: 126-8.
44. Trives MZ, Llácer JM, Escudero MA, Pastor CJ. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. J Clin Psychopharmacol 2013; 33: 538-41.
45. Paulzen M, Gründer G. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. Int J Neuropsychopharmacol 2007; 10: 149-51.
46. Lee BJ, Lee SJ, Kim MK, Lee JG, Park SW, Kim GM, et al. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci 2013; 11: 60-6.
47. Hazra M, Mamo DC, Remington G. Adjunctive versus monotherapeutic treatment for schizophrenia: Addressing antipsychotic side effects. Am J Psychiatry 2008; 165: 396-7.
48. de Bartolomeis A, Avvisati L, Iasevoli F, Tomasetti C. Intracellular pathways of antipsychotic combined therapies: Implication for psychiatric disorders treatment. Eur J Pharmacol 2013; 718(1-3): 502-23.
49. Correll CU, Gallego JA. Antipsychotic polypharmacy: A comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am 2012; 35: 661-81.
50. Grech P, Taylor D. Long-term antipsychotic polypharmacy: How does it start, why does it continue? Ther Adv Psychopharmacol 2012; 2: 5-11.
51. Anghelescu I, Wolf J. Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: A case report. J Clin Psychiatry 2004; 65: 1286-7.
52. Saitis M, Papazisis G, Katsigiannopoulos K, Kouvelas D. Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia. Psychiatry Clin Neurosci 2008; 62: 624.
53. Chen CH, Huang MC, Lu ML. Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 893-4.
54. Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 714-7.
55. Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1978-81.
56. Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 2000; 61: 833-40.
57. Peuskens J. Switching approach in the management of schizophrenia patients. Int Clin Psychopharmacol 2000; 15: 15-9.
58. Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008; 69: 1046-56.
59. Raja M. Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole. Int J Neuropsychopharmacol 2007; 10: 107-10.
60. Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 2003; 64 (Suppl 16): 24-33.
61. Mohamed S, Rosenheck R, Harpaz-Rotem I, Leslie D, Sernyak MJ. Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. Psychiatr Q 2009; 80: 241-9.
62. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152-63.
63. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 2009; 373: 31-41.
64. Kuloglu M, Ekinci O, Albayrak Y, Caykoylu A. Benefits of switching women schizophrenic patients to aripiprazole: A case study and brief review of the literature. Arch Womens Ment Health 2010; 13: 443-7.
65. Broekhof R, Gosselink MJ, Pijl H, Giltay EJ. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis. Gen Hosp Psychiatry 2012; 34: 209. e1-3.
66. Wix-Ramos RJ, Paez R, Capote E, Ezequiel U. Pituitary microadenoma treated with antipsychotic drug aripiprazole. Recent Pat Endocr Metab Immune Drug Discov 2011; 5: 58-60.
67. Ishitobi M, Kosaka H, Takahashi T, Yatuga C, Asano M, Tanaka Y, et al. Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: A proprospective open-label study. Clin Neuropharmacol 2013; 36: 151-6.
68. Voicu V, Medvedovici A, Ranetti AE, Rǎdulescu FŞ. Drug-induced hypo-and hyperprolactinemia: Mechanisms, clinical and therapeutic consequences. Expert Opin Drug Metab Toxicol 2013; 9: 955-68.
69. Pae CU, Serretti A, Chiesa A, Mandelli L, Lee C, Lee C, et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study. Eur Neuropsychopharmacol 2009; 19: 562-70.
70. Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: Meta-analysis of randomized controlled trials. PLoS One 2013; 8: e70179.
71. Xu LP, Ji JY, Shi H, Zhai FL, Zhang B, Shao Y, et al. A control study of aripiprazole in the treatment of hyperprolactinemia by antipsychotics. Chin J of Behavioral Med Sci 2006; 8: 718-20.
72. Ji JY, Song ZX, Xu LP, Sun J, Shi JA, Zhang HY, et al. Aripiprazole in treatment of female schizophrenics with risperldone induced hyperprolactinemia. Chin J Psychiatry 2008; 41: 169-71.
73. Kelly DL, Wehring HJ, Earl AK, Sullivan K, Dickerson FB, Feldman S, et al. Treating symptomatic hyperprolactinemia in women with schizophrenia: Presentation of the ongoing DAAMSEL clinical trial (Dopamine partial agonist, aripiprazole, for the management of symptomatic elevated prolactin). BMC Psychiatry 2013; 13: 214.
74. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999; 288: 774-81.
75. Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Receptor reservedependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol 2009; 607: 35-40.
76. Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptormediated signaling pathways. Neuropsychopharmacology 2007; 32: 67-77.
77. Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M, Leduc N, et al. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 2006; 535: 135-44.
78. De Berardis D, Serroni N, Moschetta FS, Martinotti G, Di Giannantonio M. Reversal of aripiprazole-induced tardive akathisia by addition of pregabalin. J Neuropsychiatry Clin Neurosci 2013; 25: E9-10.
79. Carboni L, Negri M, Michielin F, Bertani S, Fratte SD, Oliosi B, et al. Slow dissociation of partial agonists from the D receptor is linked to reduced prolactin release. Int J Neuropsychopharmacol 2012; 15: 645-56.
80. Culler, M.D., Melmed, S. Shimon, I. Method of treating hyperprolactinemia and prolactinomas. US5972893 (1999).
81. Bercu, B.F., Walker, R.F. Treatment of hyperprolactinemia. US5246920 (1993).
82. Bilgic, M. Pharmaceutical formulations comprising aripiprazole. WO2013100878 (2013).
83. Kostanski, J.W., Faburesu, T.C., Nerurkar, M., Naringrekar, V.H. Controlled release sterile injectable aripiprazole formulation and method. EP1675573 (2012).
84. Albayrak Y, Beyazyüz M, Beyazyüz E, Kuloǧlu M. Increased serum prolactin levels in drug-naive first-episode male patients with schizophrenia. Nord J Psychiatry 2013; [Epub of ahead schedule].
85. Segal M, Avital A, Berstein S, Derevenski A, Sandbank S, Weizman A. Prolactin and estradiol serum levels in unmedicated male paranoid schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 378-82.
86. Steinhagen CK. Normalization of prolactin with aripiprazole in a patient with psychotic depression and a comorbid pituitary microadenoma. Psychosomatics 2007; 48: 350-1.
87. Ng KW, Lee J, Swapna V. Management of a patient with schizophrenia and underlying pituitary macroadenoma. Ann Acad Med Singapore 2010; 39: 868-9.
88. Tsigkaropoulou E, Peppa M, Zompola C, Rizos E, Xelioti I, Chatziioannou S, et al. Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis. Gend Med 2012; 9: 56-60.